Login to Your Account

China's Generon brings IL-22 candidate to the U.S. for GvHD trial

By Shannon Ellis
Staff Writer

Tuesday, May 5, 2015

SHANGHAI – China may not be known for innovation, but Generon Corp. Ltd.'s founders decided 12 years ago they were not going to let that stop them from developing a potentially first-in-class biologic: F-652, a recombinant protein containing human interleukin 22 (IL-22).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription